Levothyroxine (Synthroid) After 65: What Older Women Need to Know

Why Thyroid Management Changes at 65

Turning 65 is not just a birthday milestone for your thyroid prescription. The physiology of how your body handles levothyroxine shifts in ways that directly affect the dose you need and the TSH level you should be aiming for.

In your reproductive years, estrogen influenced thyroid-binding globulin (TBG) levels, which affected how much free T4 circulated. After menopause, TBG falls, meaning more free T4 is available from the same dose. At the same time, renal clearance slows with age, so the drug itself stays in your system longer. The combined effect is that the same milligram dose you took at 45 can produce higher free T4 levels at 70, sometimes pushing you into subclinical or overt over-replacement without any change to your prescription.

How Aging Alters Levothyroxine Pharmacokinetics

Levothyroxine is absorbed in the small intestine, and absorption efficiency drops with age. Studies suggest absorption falls from roughly 80% in young adults to closer to 60 to 70% in older adults, partly because gastric acid secretion declines and partly because atrophic gastritis becomes more common. Atrophic gastritis and hypothyroidism frequently co-occur, so the condition that causes malabsorption is the same one that raises hypothyroid risk in older women.

Despite lower absorption, the slower renal elimination and reduced volume of distribution in a woman with less lean muscle mass means the drug's half-life extends. Net result: unpredictable, but often higher-than-expected, free T4 for a given dose.

TSH Reference Ranges Shift With Age

The classic TSH "normal range" of roughly 0.5 to 4.5 mIU/L was built largely on younger populations. Several large epidemiological studies, including the NHANES III data analysis, found that median TSH rises with age in healthy older adults who have no thyroid disease and no thyroid antibodies. NHANES data confirmed that the 97.5th percentile TSH in adults over 80 approaches 7.5 mIU/L, compared with about 4.5 mIU/L in younger adults.

This means a TSH of 5.0 mIU/L in a 72-year-old woman on levothyroxine may not represent under-treatment at all. It may be exactly where her body should be.

The Right TSH Target After 65: Why "Lower Is Not Better"

For decades, many clinicians pushed TSH to the lower end of the normal range, assuming that mimicking the thyroid output of a healthy 35-year-old was the goal. For women over 65, particularly those who are postmenopausal, the evidence has shifted firmly against that approach.

The Leiden 85-Plus Study showed that in adults over 85, higher TSH levels were associated with better survival, not worse. The benefit of keeping TSH slightly elevated in older adults likely reflects protection from the cardiovascular and skeletal harms of excess thyroid hormone.

Cardiovascular Risk of Over-Replacement in Older Women

Atrial fibrillation (AF) is the most immediate cardiac danger of a suppressed TSH. A TSH below 0.1 mIU/L triples the risk of AF over 10 years, based on the Framingham Heart Study. Women develop AF at older ages than men on average, but once AF is present, women face a higher stroke risk than men with the same arrhythmia. This sex difference matters: the CHA2DS2-VASc scoring system assigns one point simply for female sex in the context of AF.

Postmenopausal women also lose the cardiovascular protection that estrogen provided during their reproductive years. Excess thyroid hormone raises heart rate and blood pressure and increases left ventricular mass. For a woman already managing hypertension or diastolic dysfunction, both more common after menopause, even mild over-replacement adds meaningful cardiac load.

Bone Loss: The Underappreciated Risk for Postmenopausal Women

After menopause, bone turnover accelerates because estrogen is no longer suppressing osteoclast activity. Levothyroxine at suppressive doses acts on bone in the same direction: it increases osteoclast activity and accelerates cortical bone loss.

A 1992 meta-analysis published in JAMA found that postmenopausal women on suppressive levothyroxine therapy had significantly lower bone mineral density (BMD) at the femoral neck and lumbar spine compared with those on replacement doses. The premenopausal women in the same analysis did not show the same bone loss, confirming this is a postmenopausal-specific risk driven by the loss of estrogen's protective effect on bone.

If your TSH is consistently below 0.5 mIU/L and you are postmenopausal, a DEXA scan is warranted. The American Thyroid Association's guidelines recommend that postmenopausal women on suppressive thyroid hormone therapy receive bone density monitoring.

Transitioning From Mid-Life to Geriatric Dosing

If you were diagnosed with hypothyroidism in your 40s or 50s and your dose was set during that period, it almost certainly needs to be revisited now. This is one of the most consistently overlooked steps in women's primary care.

How Dose Adjustments Are Made

Levothyroxine is dosed by lean body weight, typically starting at 1.6 mcg/kg/day in younger adults. In women over 65, most endocrinologists start closer to 1.0 to 1.2 mcg/kg/day and titrate upward only if TSH remains above target after 6 to 8 weeks. The American Association of Clinical Endocrinology (AACE) recommends starting at lower doses in older patients and titrating slowly.

Dose increments should be small: 12.5 mcg or 25 mcg at a time, with a minimum 6-week wait before the next adjustment. Rushing the titration in older women risks over-shooting the target and triggering cardiac or bone complications.

Subclinical Hypothyroidism: To Treat or Not to Treat After 65

This question is more contested than most clinicians admit. Subclinical hypothyroidism (TSH elevated, free T4 normal) affects roughly 10 to 15% of women over 65. The TRUST trial, a randomized controlled trial of 737 adults over 65 with subclinical hypothyroidism published in NEJM in 2017, found no improvement in symptoms, quality of life, or thyroid-related outcomes with levothyroxine treatment compared with placebo.

This finding was significant. It challenged the assumption that every elevated TSH in an older woman needs a prescription. The takeaway for clinical practice: in the absence of symptoms, very high TSH (above 10 mIU/L), or specific risk factors like heart failure or pregnancy (not applicable at 65+), watchful waiting with annual TSH monitoring is a defensible option.

When Treatment Is Clearly Indicated

Treatment at any age, including 65+, is appropriate when TSH is above 10 mIU/L, when free T4 is low, when symptoms are clearly attributable to hypothyroidism (cold intolerance, weight gain despite low intake, slowed cognition), or when there is clinical evidence of heart failure or dyslipidemia worsened by thyroid deficiency.

Drug Interactions That Hit Harder After 65

Older women take more medications. That is simply a fact. And many of the drugs commonly prescribed after 65 interfere with levothyroxine absorption or metabolism in ways that can either cause under-treatment or over-treatment.

Absorption Blockers: Timing Is Everything

The following medications blunt levothyroxine absorption if taken within 4 hours of the thyroid pill:

• Calcium carbonate (the most common form in bone supplements)
• Calcium citrate (slightly less of an effect, but still significant)
• Ferrous sulfate and other iron supplements
• Proton pump inhibitors (omeprazole, pantoprazole) used for GERD
• Antacids containing aluminum or magnesium
• Cholestyramine and other bile acid sequestrants used for cholesterol
• Sucralfate

A randomized crossover study published in the Annals of Internal Medicine confirmed that calcium carbonate reduces levothyroxine absorption by approximately 20 to 39% when taken simultaneously. For a postmenopausal woman taking both a calcium supplement for osteoporosis and levothyroxine, this interaction is nearly universal and consistently undertreated in clinical practice.

The fix is simple but requires deliberate habit: take levothyroxine on an empty stomach first thing in the morning, at least 30 to 60 minutes before food, coffee, or any other medication. If morning dosing is not feasible (which happens with complex medication schedules in older adults), bedtime dosing at least 3 to 4 hours after the last meal is an evidence-supported alternative. A 2007 study in Clinical Endocrinology found that bedtime levothyroxine produced better TSH control than morning dosing in a population with documented absorption interference.

Medications That Increase Levothyroxine Clearance

Certain drugs speed up the liver's metabolism of thyroid hormone through CYP enzyme induction. Rifampicin, carbamazepine, phenytoin, and phenobarbital all reduce circulating thyroid hormone levels. If an older woman starts one of these agents, her TSH should be rechecked in 6 weeks, not at the next annual visit.

Postmenopausal Women: The Intersection of Thyroid, Bone, and Hormones

This section is specific to women who are postmenopausal and taking levothyroxine, because this combination creates a clinical situation that requires a different monitoring approach than in younger women or men.

Hormone Therapy and Levothyroxine: What Changes

If you start menopausal hormone therapy (MHT) while already taking levothyroxine, your dose may need to go up. Oral estrogen raises TBG, which binds more T4 and reduces free T4. Studies have consistently shown that women starting oral estrogen therapy require a levothyroxine dose increase of approximately 25 to 50 mcg to maintain the same TSH. Transdermal estrogen has a much smaller effect on TBG and typically does not require a dose change.

This is a direct, practical reason why TSH should be rechecked 6 to 8 weeks after starting or stopping any form of oral MHT.

Bone Monitoring Protocol for Women on Levothyroxine After 65

Below is a monitoring framework specific to postmenopausal women on levothyroxine, synthesized from AACE guidelines, American Thyroid Association recommendations, and bone health evidence. No single published source combines these into one protocol for this population.

Tier 1: Replacement dosing (TSH 4.0 to 6.0 mIU/L) DEXA at baseline; repeat every 3 to 5 years or per standard osteoporosis screening guidelines. Annual TSH. No additional thyroid-specific bone monitoring needed.

Tier 2: Mildly suppressed TSH (0.5 to 3.9 mIU/L) on standard replacement DEXA at baseline and every 2 years. Review whether dose can be reduced while keeping TSH in the 4 to 6 range appropriate for age.

Tier 3: Suppressed TSH (below 0.5 mIU/L), most often seen in women treated for differentiated thyroid cancer requiring TSH suppression: DEXA annually. Discuss antiresorptive therapy (bisphosphonate or denosumab) with your clinician if T-score is below -2.0. Reassess the oncologic necessity of continued suppression at least annually.

Women in Tier 3 who are also postmenopausal and not on antiresorptives represent the highest-risk group for thyroid-related bone loss.

Cognitive Symptoms and Thyroid Function in Older Women

Cognitive slowing is one of the hallmark symptoms of hypothyroidism at any age. After 65, it overlaps substantially with normal age-related cognitive change and early neurodegenerative disease, making the attribution difficult.

A treated TSH in the over-replaced range can itself cause cognitive symptoms, including anxiety, poor sleep, and difficulty concentrating, that mimic hypothyroid cognitive fog. A 2019 analysis in JAMA Internal Medicine found no cognitive benefit of levothyroxine treatment in adults over 65 with subclinical hypothyroidism, consistent with the TRUST trial's broader findings.

This does not mean thyroid function is irrelevant to cognition after 65. Overt hypothyroidism with a low free T4 absolutely warrants treatment and can cause reversible cognitive decline. The point is that optimizing TSH to the low-normal range does not appear to produce cognitive gains in older women with subclinical disease.

Pregnancy and Lactation Safety

Levothyroxine is a synthetic version of a hormone your body naturally produces. At replacement doses that maintain a normal thyroid axis, levothyroxine is not teratogenic and is safe in pregnancy.

This section is included because some women in their early 60s who carried a pregnancy in their 40s or who manage fertility preservation questions for younger family members often ask about what the rules were, and because a small number of women in their early-to-mid 60s who conceived through assisted reproduction with donor eggs have asked this question directly.

Pregnancy Category and Human Data

Levothyroxine has been assigned FDA Pregnancy Category A, meaning adequate and well-controlled studies in pregnant women have not shown risk to the fetus. Maternal hypothyroidism, by contrast, is clearly harmful: it is associated with miscarriage, preterm birth, impaired fetal neurodevelopment, and placental abruption. Untreated or under-treated hypothyroidism in pregnancy is the risk, not the drug itself.

TSH targets in pregnancy differ substantially from geriatric targets: ACOG and the Endocrine Society recommend maintaining TSH below 2.5 mIU/L in the first trimester, which requires dose increases of 20 to 30% from pre-pregnancy levels, often starting within the first few weeks of confirmed pregnancy.

Lactation

Levothyroxine passes into breast milk in small amounts, but the concentrations are physiologically trivial. LactMed, the NIH's lactation drug database, rates levothyroxine as compatible with breastfeeding. No dose adjustment is required for lactating women beyond what TSH monitoring dictates.

Contraception Note

Levothyroxine itself does not require contraception. The drug is not a teratogen at replacement doses. However, hypothyroidism impairs fertility, and optimally treated hypothyroid women on levothyroxine who do not wish to become pregnant should use their chosen method of contraception independently.

Who This Approach Is Right For (and Who Needs a Different Conversation)

Right for:

• Women 65 and older who have been on levothyroxine since their 40s or 50s and have never had their dose reconsidered in the context of aging
• Postmenopausal women whose TSH is persistently below 1.0 mIU/L without clear oncologic or symptomatic reason
• Women who recently started or stopped oral menopausal hormone therapy and have not had TSH rechecked
• Women taking calcium supplements or proton pump inhibitors without knowing about the absorption interaction
• Women with osteopenia or osteoporosis who are on levothyroxine and have not had DEXA monitoring in more than 3 years

May need a different approach:

• Women with differentiated thyroid cancer (papillary or follicular) where TSH suppression is intentional and oncologically directed. Bone protection, not dose reduction, is the strategy here.
• Women with significant symptomatic hypothyroidism (TSH above 10 mIU/L, low free T4). These women should not delay treatment regardless of age.
• Women with severe cardiac disease where any dose change carries higher risk. Cardiology input is appropriate before adjusting thyroid dosing in this group.

Practical Monitoring Checklist for Women 65+

A straightforward approach to managing levothyroxine after 65 looks like this:

• TSH every 6 weeks after any dose change, any new interfering medication, or any change in estrogen therapy
• TSH annually once dose is stable and TSH is in target range
• Free T4 checked alongside TSH whenever TSH is out of range or symptoms are present
• DEXA at baseline and on schedule determined by TSH tier (see framework above)
• Medication timing review at every visit: calcium, iron, PPIs, and antacids are the most common culprits for dose instability in this age group
• Annual review of whether the original diagnosis still stands. Some older women were diagnosed with subclinical hypothyroidism decades ago and have never had a dose-free trial to see whether they still require treatment

Maya Okafor, MD, WomanRx medical reviewer and board-certified OB-GYN with subspecialty training in reproductive endocrinology, states: "The most common error I see in older women on levothyroxine is a dose that was set at 50 or 55 and never touched again. A 70-year-old woman who has lost lean mass, gone through menopause, and started a proton pump inhibitor is pharmacologically a completely different patient than she was 15 years ago. TSH should be rechecked every time her health context changes, not just once a year by rote."